X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35) 35
humans (24) 24
hematology (23) 23
oncology (18) 18
mutation (17) 17
animals (11) 11
article (11) 11
leukemia (11) 11
myelofibrosis (11) 11
male (10) 10
mice (10) 10
polycythemia-vera (10) 10
essential thrombocythemia (9) 9
abridged index medicus (8) 8
medicine, research & experimental (8) 8
myeloproliferative neoplasms (8) 8
somatic mutations (8) 8
aged (7) 7
hemic and lymphatic diseases (7) 7
mutations (7) 7
ruxolitinib (7) 7
acute myeloid-leukemia (6) 6
analysis (6) 6
cancer (6) 6
care and treatment (6) 6
chronic myelomonocytic leukemia (6) 6
female (6) 6
food and beverages (6) 6
gene mutations (6) 6
genetic aspects (6) 6
middle aged (6) 6
prognosis (6) 6
therapy (6) 6
tyrosine kinase jak2 (6) 6
cell biology (5) 5
janus kinase 2 - genetics (5) 5
myelodysplastic syndrome (5) 5
myelodysplastic syndromes (5) 5
myeloid metaplasia (5) 5
neoplasms (5) 5
signal transduction (5) 5
treatment outcome (5) 5
activating mutation (4) 4
acute myeloid leukemia (4) 4
adult (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
classification (4) 4
disease (4) 4
glycosylation (4) 4
leukemia, myeloid, acute - genetics (4) 4
melanoma (4) 4
myeloid neoplasia (4) 4
primary myelofibrosis (4) 4
research (4) 4
tumors (4) 4
activation (3) 3
acute lymphoblastic-leukemia (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
biochemistry & molecular biology (3) 3
cell proliferation - drug effects (3) 3
disease progression (3) 3
disorders (3) 3
drug therapy (3) 3
expression (3) 3
fucose - metabolism (3) 3
gene (3) 3
genetics (3) 3
health aspects (3) 3
hematopoietic stem (3) 3
hematopoietic stem cells (3) 3
inhibition (3) 3
langerhans cell histiocytosis (3) 3
leukemic transformation (3) 3
medical colleges (3) 3
medical research (3) 3
medicine, experimental (3) 3
membrane proteins - genetics (3) 3
membrane proteins - metabolism (3) 3
myeloproliferative disorders - diagnosis (3) 3
myeloproliferative disorders - drug therapy (3) 3
myeloproliferative disorders - genetics (3) 3
phenotype (3) 3
protein kinase inhibitors - adverse effects (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
receptors, thrombopoietin - genetics (3) 3
risk assessment (3) 3
transplantation (3) 3
vemurafenib (3) 3
aged, 80 and over (2) 2
antineoplastic agents - pharmacology (2) 2
autosomal-dominant arteriopathy (2) 2
available therapy (2) 2
bone marrow - pathology (2) 2
bone-marrow fibrosis (2) 2
braf mutations (2) 2
brain - pathology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 1930 - 1930
Abstract Ruxolitinib is an orally available JAK1/2 inhibitor FDA approved for the treatment of myelofibrosis and polycythemia vera. Evidence suggest the effect... 
Journal Article
Cancer treatment and research, ISSN 0927-3042, 2019, Volume 179, p. 159
The myeloproliferative neoplasms (MPNs) are clonal stem cell-derived diseases. This chapter focuses on the subcategory of Philadelphia (Ph) chromosome-negative... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5583 - 5583
Background: About 25% of individuals with essential thrombocythemia (ET) harbor a somatic mutation of the cal reticulin (CALR) gene which is thought to be the... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1677 - 1677
MPN-BP originates from a leukemic stem cell (LSC) that is capable of recreating and serial passaging the leukemia in NSG mice (Wang Blood 2018). The genomic... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 634 - 634
Abstract Ruxolitinib has demonstrated significant benefits for patients with MPNs, including reduction of splenomegaly and improvement in symptom burden.... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4207 - 4207
The TP53 pathway has been shown to be dysregulated in myeloproliferative neoplasms (MPN) through several different mechanisms, including TP53 mutations, TP53... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2967 - 2967
Background: The introduction of the JAK1/2 inhibitor Ruxolitinib has resulted in significant benefits for patients with Myelofibrosis (MF) and Polycythemia... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1809 - 1809
Abstract Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder that is characterized by cytopenias, organomegaly,... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 101 - 101
Abstract Myeloproliferative neoplasm-blast phase (MPN-BP) and de novo acute myeloid leukemia (AML) each have distinct mutational patterns and clinical courses.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 87 - 87
Abstract Genomic analyses have recently illuminated our understanding of therapy-associated myeloid neoplasms in patients receiving therapy for other cancers.... 
Journal Article
Current Opinion in Hematology, ISSN 1065-6251, 03/2015, Volume 22, Issue 2, pp. 177 - 183
Journal Article
Blood, ISSN 0006-4971, 2016, Volume 127, Issue 24, pp. 3004 - 3014
Journal Article
LEUKEMIA, ISSN 0887-6924, 11/2019, Volume 33, Issue 11, pp. 2753 - 2757
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1681 - 1681
Background The Myeloproliferative Neoplasms, including Essential Thrombocythemia (ET), Polycythemia Vera (PV), and Myelofibrosis (MF) are stem cell disorders... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4163 - 4163
Background: Anemia and thrombocytopenia are common in myelofibrosis (MF), and portend adverse outcomes. Few effective modalities to address these cytopenias... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1661 - 1661
Background: Pegylated Interferon-alpha (PEG-IFNa) improves hematologic parameters and reduces mutant allele fraction in patients with myeloproliferative... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1757 - 1757
Abstract Introduction: MF is a Philadelphia-negative myeloproliferative neoplasm (Ph-negative MPN) with an heterogeneous outcome. In 2009, Cervantes et al.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 233 - 233
Abstract There is no standard therapy for patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMA) and the median overall... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.